Nasdaq: PBLS · Listed Jun 10, 2026
Parabilis Medicines IPO
IPO price
$20.00
Parabilis Medicines (PBLS) priced its IPO at $20.00 a share and has traded on Nasdaq since Jun 10, 2026.
PBLS today$26.77+33.85%since IPO15-min delayed · as of 4:02:15 AM EST on Nov 19, 2026
See the PBLS quoteFirst trading day · Jun 10, 2026
- IPO price
- $20.00
- above the range of $17 to $19
- First trade
- $33.35
- +66.75% from the IPO price
- First-day last trade
- $32.24
- +61.22% from the IPO price, regular session
- Raise
- $670M
- before the underwriters' option
These numbers are from the first trading day, Jun 10, 2026.
How PBLS did against the market
PBLS against the market, from its first trade at 12:45 ET to the last trade of the session.
- PBLS from its first trade
- -3.31%
- Against the market (QQQ)
- -2.5 pts
PBLS fell 3.3% from its first trade to the last trade of the session. That is 2.5 points worse than the market.
Same-day moves do not show that PBLS caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
PBLS against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
PBLS against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Parabilis Medicines '26 | $670M | +66.75% | +61.22% | +32.25% | +64.25% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Parabilis Medicines IPO offers 33.5M shares to raise $670M, before any underwriters' option.
- Expected price range
- $17 to $19
- IPO price
- $20.00
- Shares offered
- 33.5M
- Money raised
- $670M
- Listing date
- Jun 10, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Parabilis Medicines$670M
Where PBLS ranks
Parabilis Medicines's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- PBLS$3.57B
PBLS news
The latest news and headlines about Parabilis Medicines (PBLS).
- Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?positiveZacks Investment Research· Nov 17, 2026
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid TumorspositiveGlobeNewswire Inc.· Oct 24, 2026
- Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of DirectorspositiveGlobeNewswire Inc.· Aug 25, 2026
- Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?neutralThe Motley Fool· Jun 12, 2026
- Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharespositiveBenzinga· Jun 11, 2026
Filings and the company
What Parabilis Medicines has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Parabilis Medicines discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Parabilis Medicines, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.
- Lease agreementNov 5, 2026
On October 30, 2026, Parabilis Medicines, Inc. and LS 400/500 CDP, LLC entered into a Third Amendment of Lease, which amends the Lease regarding the Company's corporate headquarters located at 30 Acorn Park Drive, Cambridge, Massachusetts. The Amendment provides for an expansion, beginning on January 1, 2028, of the leased space by a total of 33,525 square feet at 20 Acorn Park Drive, an extension of the lease term through December 31, 2037, and options for further five-year extensions.
- Executive compensation changeSep 2, 2026
In connection with his departure from the Company, Dr. Benzaghou will receive severance benefits pursuant to the terms of his employment agreement with the Company.
- Executive compensation changeAug 25, 2026
In accordance with the Company's compensation program for non-employee directors, Mr. Tendler received an equity award consisting of a stock option to purchase 20,294 shares of the Company's common stock at an exercise price of $39.36 per share. The option award will vest in thirty-six substantially equal monthly installments over three years from the date of grant... Mr. Tendler will also receive an annual retainer of $40,000 for Board service and $7,500 for Science & Technology Committee service, each to be paid quarterly in arrears.
- Investor presentationAug 13, 2026
On August 13, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the investor relation page of the Company's website at https://parabilismed.com/. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
About Parabilis Medicines
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
- Ticker
- PBLS
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Listed
- Jun 10, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Parabilis Medicines IPO price?
$20.00 a share.
When did Parabilis Medicines go public?
Parabilis Medicines listed on Nasdaq on Jun 10, 2026 under the ticker PBLS.
How much did the Parabilis Medicines IPO raise?
$670M, before any underwriters' option.
How did Parabilis Medicines open on its first day?
PBLS first traded at $33.35, +66.75% from the IPO price of $20.00.
How did PBLS close on its first day?
Its last regular-session trade was $32.25, +61.22% from the IPO price of $20.00.
What was the PBLS first-day trading range?
$26.61 to $34.02 in the regular session.
How many PBLS shares traded on the first day?
5.32M shares in the regular session.
How many shares did Parabilis Medicines sell in its IPO?
33.5M shares.
How did PBLS do against the market on its first day?
PBLS fell 3.3% from its first trade to the last trade of the session. That is 2.5 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is PBLS listed on?
Parabilis Medicines lists on Nasdaq under the ticker PBLS.
Build with Massive
Get the PBLS data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/PBLS/range/5/minute |
| Market cap | /v3/reference/tickers/PBLS |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.